• Due to excessive bot signups along with nefarious actors we are limiting forum registration. Keep checking back for the register link to appear. Please do not send emails or have someone post to the forum asking for a signup link. Until the current climate changes we do not see a change of this policy. To join the forum you must have a compelling reason. Letting us know what skills/knowledge you will bring to the community along with the intent of your stay here will help in getting you approved.

Oral testosterone + vitamin E may treat NAFLD, NASH, cirrhosis in humans

haidut

Member
Joined
Mar 18, 2013
Messages
18,409
Location
USA / Europe
Several years ago, I posted a few studies from the 1970s demonstrating very high cure rates of advanced cirrhosis in humans with a combination treatment of testosterone (T) and vitamin B1 (thiamine). Not bad for a condition modern medicine tells us is incurable and the only option the patient has is a liver transplant.

[ON 2 CASES OF ASCITES DUE TO HEPATIC CIRRHOSIS IN SUBJECTS OPERATED ON BY SPLENECTOMY AND PRESENTING PORTA OBLITERATION--CLINICAL RECOVERY FOLLOWING TREATMENT WITH HIGH DOSES OF TESTOSTERONE AND VITAMIN B 1] - PubMed
[Possible clinical cure in a high percentage of cases of liver cirrhosis with a treatment based on high doses of testosterone and vitamin B 1] - PubMed
[THERAPY OF LIVER CIRRHOSIS WITH TESTOSTERONE AND VITAMIN B 1] - PubMed
https://www.tandfonline.com/doi/abs/10.1080/00325481.1964.11694984

In those studies, the administration of both T and B1 was by injection, however the doses were not that high. The average daily dose of T was about 25mg daily and B1 dosage was just 50mg twice a week. Now, a series of recent studies below demonstrates that using only the T component of the combination treatment is also effective, and the administration can be done orally. The T formulation (LPCN 1144) used in the human studies below was in the form of the undecanoate ester mixed with a "proprietary" lipid emulsion, which allows that T to avoid first-pass metabolism through the liver and reach the systemic circulation through the lymphatic system. If that description sounds familiar, it is probably because Peat's product Progest-E is based on the same idea and Peat has been speaking for decades about combining steroids with longer chain fats as a method of achieve high bioavailability of steroids when used orally. To make matters even more suspiciously plagiaristic, one of the studies administered the T formulation together with vitamin E and found that the beneficial effects were even stronger. I suppose the only reason the company Lipocine, Inc did not develop a T formulation dissolved in vitamin E is the patent Peat filed on such formulations, which prevents Lipocine using the idea without paying Peat royalties. Be that as it may, at least we have proof from clinical trials that Peat's method for oral steroid delivery works and is quite effective at treating even "incurable" conditions. The dosages used in the human studies below were 142mg LCN 1144 (testosterone formulation) twice daily and 217 mg alpha-tocopherol once daily. The route of administration was oral and treatment period was up to 36 weeks.

LPCN 1144 - Lipocine
A Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH) - Full Text View - ClinicalTrials.gov
Lipocine (LPCN) Reports Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience™

"...Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present a poster with results from a preclinical study investigating LPCN 1144 treatment on hepatic fibrosis and non-alcoholic steatohepatitis ("NASH") features at The Liver Meeting Digital Experience™, hosted by the American Association for the Study of Liver Diseases ("AASLD"). The poster will be available virtually on Friday, November 13, 2020, Room 1970 between 6:00 AM - 11:55 PM ET.

"It has been shown that low testosterone levels in men are independently associated with the presence and severity of NASH," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc. Dr. Patel further stated, "These preclinical data add to our understanding of the effects of oral testosterone on the liver, showing that LPCN 1144 improved high fat diet induced hepatic fibrosis and NASH features."

"...Both the LPCN 1144 and LPCN 1144+AT arms improved mean histological scores of NASH with fibrosis compared to HFD arm. Importantly, the fibrosis percentage (in sampled liver tissue area) was significantly improved in both the LPCN 1144 (p<0.05) and LPCN 1144+AT (p=0.05) treatment arms vs the HFD arm. Both LPCN 1144 and LPCN 1144+AT arms also reduced HFD-induced elevated liver mRNA inflammation and fibrosis markers. Furthermore, LPCN 1144 concomitant treatment improved insulin resistance, visceral adiposity, and low testosterone (metabolic dysfunctions) induced by HFD."

"...In the ongoing randomized, double-blind, placebo-controlled 36-week treatment LiFT study, subjects with F1-F3 fibrosis were randomized 1:1:1 to one of three arms (Treatment A is a twice daily oral dose of 142 mg testosterone equivalent, Treatment B is a twice daily oral dose of 142 mg testosterone equivalent formulated with 217 mg of d-alpha tocopherol equivalent, and the third arm is twice daily matching placebo). The primary endpoint is change in hepatic fat fraction via Magnetic Resonance Imaging Proton Density Fat Fraction ("MRI-PDFF") and exploratory liver fat/marker end points post 12 weeks of treatment. Additionally, key secondary endpoints post 36 weeks of treatment include assessment of histological change for NASH resolution and/or fibrosis improvement as well as liver fat data."
 

johnwester130

Member
Joined
Aug 6, 2015
Messages
3,230
A DHEA product in vitamin E would be very interesting

The vitamin E attaches the steroid to chylomicrons, that other solvents don't do
 

Belsazar

Member
Joined
May 16, 2016
Messages
108
"It has been shown that low testosterone levels in men are independently associated with the presence and severity of NASH," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc. Dr. Patel further stated, "These preclinical data add to our understanding of the effects of oral testosterone on the liver, showing that LPCN 1144 improved high fat diet induced hepatic fibrosis and NASH features."
Just some questions for anyone to chime in:
Is the underlying mechanism for low testosterone in this condition known? Is DHT affected as well (so anti-androgenic treatments such as Finasteride induce liver steatosis)? Is it causally linked to poor liver function (less androgen production) or is low testosterone (androgens) the reason why the liver isn't working well? Aren't low fat diets associated with lower testosterone (contradiction)?

As Lipocine is still in medical trial, at what testosterone levels would doctors consider TRT in case of steatohepatitis (I doubt they would since there is no approved treatment)?
 

Sexypizza

Member
Joined
Mar 18, 2017
Messages
152
Several years ago, I posted a few studies from the 1970s demonstrating very high cure rates of advanced cirrhosis in humans with a combination treatment of testosterone (T) and vitamin B1 (thiamine). Not bad for a condition modern medicine tells us is incurable and the only option the patient has is a liver transplant.

[ON 2 CASES OF ASCITES DUE TO HEPATIC CIRRHOSIS IN SUBJECTS OPERATED ON BY SPLENECTOMY AND PRESENTING PORTA OBLITERATION--CLINICAL RECOVERY FOLLOWING TREATMENT WITH HIGH DOSES OF TESTOSTERONE AND VITAMIN B 1] - PubMed
[Possible clinical cure in a high percentage of cases of liver cirrhosis with a treatment based on high doses of testosterone and vitamin B 1] - PubMed
[THERAPY OF LIVER CIRRHOSIS WITH TESTOSTERONE AND VITAMIN B 1] - PubMed
https://www.tandfonline.com/doi/abs/10.1080/00325481.1964.11694984

In those studies, the administration of both T and B1 was by injection, however the doses were not that high. The average daily dose of T was about 25mg daily and B1 dosage was just 50mg twice a week. Now, a series of recent studies below demonstrates that using only the T component of the combination treatment is also effective, and the administration can be done orally. The T formulation (LPCN 1144) used in the human studies below was in the form of the undecanoate ester mixed with a "proprietary" lipid emulsion, which allows that T to avoid first-pass metabolism through the liver and reach the systemic circulation through the lymphatic system. If that description sounds familiar, it is probably because Peat's product Progest-E is based on the same idea and Peat has been speaking for decades about combining steroids with longer chain fats as a method of achieve high bioavailability of steroids when used orally. To make matters even more suspiciously plagiaristic, one of the studies administered the T formulation together with vitamin E and found that the beneficial effects were even stronger. I suppose the only reason the company Lipocine, Inc did not develop a T formulation dissolved in vitamin E is the patent Peat filed on such formulations, which prevents Lipocine using the idea without paying Peat royalties. Be that as it may, at least we have proof from clinical trials that Peat's method for oral steroid delivery works and is quite effective at treating even "incurable" conditions. The dosages used in the human studies below were 142mg LCN 1144 (testosterone formulation) twice daily and 217 mg alpha-tocopherol once daily. The route of administration was oral and treatment period was up to 36 weeks.

LPCN 1144 - Lipocine
A Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH) - Full Text View - ClinicalTrials.gov
Lipocine (LPCN) Reports Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience™

"...Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present a poster with results from a preclinical study investigating LPCN 1144 treatment on hepatic fibrosis and non-alcoholic steatohepatitis ("NASH") features at The Liver Meeting Digital Experience™, hosted by the American Association for the Study of Liver Diseases ("AASLD"). The poster will be available virtually on Friday, November 13, 2020, Room 1970 between 6:00 AM - 11:55 PM ET.

"It has been shown that low testosterone levels in men are independently associated with the presence and severity of NASH," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc. Dr. Patel further stated, "These preclinical data add to our understanding of the effects of oral testosterone on the liver, showing that LPCN 1144 improved high fat diet induced hepatic fibrosis and NASH features."

"...Both the LPCN 1144 and LPCN 1144+AT arms improved mean histological scores of NASH with fibrosis compared to HFD arm. Importantly, the fibrosis percentage (in sampled liver tissue area) was significantly improved in both the LPCN 1144 (p<0.05) and LPCN 1144+AT (p=0.05) treatment arms vs the HFD arm. Both LPCN 1144 and LPCN 1144+AT arms also reduced HFD-induced elevated liver mRNA inflammation and fibrosis markers. Furthermore, LPCN 1144 concomitant treatment improved insulin resistance, visceral adiposity, and low testosterone (metabolic dysfunctions) induced by HFD."

"...In the ongoing randomized, double-blind, placebo-controlled 36-week treatment LiFT study, subjects with F1-F3 fibrosis were randomized 1:1:1 to one of three arms (Treatment A is a twice daily oral dose of 142 mg testosterone equivalent, Treatment B is a twice daily oral dose of 142 mg testosterone equivalent formulated with 217 mg of d-alpha tocopherol equivalent, and the third arm is twice daily matching placebo). The primary endpoint is change in hepatic fat fraction via Magnetic Resonance Imaging Proton Density Fat Fraction ("MRI-PDFF") and exploratory liver fat/marker end points post 12 weeks of treatment. Additionally, key secondary endpoints post 36 weeks of treatment include assessment of histological change for NASH resolution and/or fibrosis improvement as well as liver fat data."


Any idea where I can acquire a testosterone supplement like the one mentioned?
 

Broken man

Member
Joined
Sep 11, 2016
Messages
1,693
@haidut, I would like to ask about possible aromatization of such huge doses of testosterone? Isnt it a problem ?
 

Similar threads

Top